Viracta Therapeutics Net Income

Viracta Therapeutics (VIRX) currently reports a net income of $-43M as of September 2024. That compares with $-49M in the prior-year period — up 10.8% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Viracta Therapeutics's net income history and peer comparisons.

Viracta Therapeutics's net income increased from $-49M to $-43M — a 10.8% year-over-year increase (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Viracta Therapeutics's net income of $-43M is lower than the Healthcare sector average of $16B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Viracta Therapeutics reported $-43M in net income as of September 2024. That compares with $-49M in the prior-year period — up 10.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-43M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Viracta Therapeutics, and consider following VIRX for alerts when major investors trade the stock.